Napoletano said that you really don’t want to know the details about who is taking the product, especially with a Schedule II opioid. It could easily lead to violations of patient-privacy laws. Another issue with failing to keep an arm’s length from the patients is that it implicates the company in any inappropriate prescribing. Having an internal division pushing for questionable patients to be approved for a narcotic—it added up to a serious potential liability. If you pay someone else to do it, you can deny playing a role.
